October 4 Biotech Update

We got some news to talk about today and it just so happens to be some good news and some bad news. In both cases, the news is specific enough.

September 21 Biotech Update

The sector did get some momentum with the news yesterday but it still feels like a grind that is in a holding pattern, although clearly not like the broader market.

September 20 Biotech Update

We are starting to get some meaningful data this week and while I suspect it will have some broader upside today, I will be curious to see if the sector.

September 15 Biotech Update

It still looks to me that the sector is acting less like a sector and more like an aggregation of individual stocks. That is always true (it is not a.

September 13 Biotech Update

The sector in general appears to be treading water at these levels but that seems to belie the larger moves under the surface. I think keeping these levels and having.

September 1 Biotech Update

They say that the market never bottoms on a Friday and I wonder if the same is true of topping? The sector has clearly had a strong near term move.

August 31 Biotech Update

The good news and move for the sector continues. In isolation the move higher seems a stretch in terms of the fundamental news that we have seen the past week..

August 20 Biotech Update

Another slow news day with a more of the same market. What looked like a developing trend of strong small cap performance has morphed back into the run of the.

Recent Option Activity (8/6 ~ 8/12)

The following stocks had recent and notable activity in their options: $INFI (8/6): 3,822 SEP 10.0 strike Puts were sold (stock at $9.98) for 0.45 or total proceeds of $171,990..

Upcoming WORLD symposium meeting

(with Jason Chew) Lysosomal Disease Network WORLD Symposium meeting The Lysosomal Disease Network (LDN) WORLD Symposium provides an interdisciplinary forum to explore and discuss specific areas of research and clinical.

Wednesday at the JP Morgan Healthcare Conference

With the JP Morgan Healthcare Conference wrapped up, I wanted to highlight some notes from the Wednesday session. I tried to keep them as concise as possible. We will say.

FOLD – Amicus approaches inflection point

With Phase 3 data expected from Amicus Therapeutics (NASDAQ : FOLD), we wanted to take the time to do a thorough analysis of the trial and what to expect. Jason.

FOLD – Getting Ready For The New Uptrend

Amicus Therapeutics, Inc. (NASDAQ: FOLD) With FOLD on the move again, we wanted to look at how the stock is performing from a technical perspective , especially after Patrick’s report.

FOLD – Bullish on Amicus Therapeutics

With Phase 3 data expected from Amicus Therapeutics (NASDAQ : FOLD), we wanted to take the time to do a thorough analysis of the trial and what to expect. Jason.

FOLD – Phase II Amigal Co-administration Update

Amicus Therapeutics released updated data Thursday for its chaperone molecule Amigal (migalastat) for Fabry disease at the American Society of Human Genetics (ASHG) Annual Meeting. Results looked good, continuing to.

FOLD – Quick Take – Amigal P3 Monotherapy

Amicus Therapeutics is expected to unveil results from its Phase III registration trial for migalastat (Amigal) as monotherapy for the treatment of Fabry disease in the third quarter of this.

A flurry of upcoming data before the end of June

With the close of the first half of 2012 upon us, we wanted to highlight some of those expected to report data or regulatory decisions before the end of June..

FOLD – Update on Amicus Therapeutics

Investors in Amicus Therapeutics (NASDAQ: FOLD) are anxiously awaiting data from several ongoing trials in rare-diseases. We initiated coverage on Amicus back in January[link]. We are waiting data from the.

FOLD – Initiating Coverage

FOLD: Initiating Coverage Overview: Now here is an interesting story. Amicus Therapeutics was founded in 2002 by serial entrepreneur and CEO John Crowley. He had previously founded Novozyme seeking a.

Browsing 20 / articles